By blocking IL-31 signaling, nemolizumab may disrupt T cell immune balance, potentially triggering inflammatory skin disorders such as bullous pemphigoid, urticaria, and psoriasiform dermatitis. Here, IL31 is linked to inflammatory skin disease.